Select another
Join us on Twitter Join us on Linkedin Become a member Subscribe to the newsletter

Luxembourg BioHealth Cluster


The Luxembourg BioHealth Cluster is a young emerging Cluster aiming to reinforce and capitalise on the National Strategy developed by the Government to achieve scientific excellence in molecular diagnostics, the cornerstone of personalised medicine, and to enhance the Grand Duchy's reputation as a recognised and attractive environment for biomedical research, development, innovation (RDI) and business.

Our members are R&D companies, public research organisations, laboratories, hospitals and other actors (patients associations, providers of capital and services…) based in Luxembourg whose activities are related to Health Sciences and Technologies. With a principal focus on molecular diagnostics, the Cluster’s umbrella also covers other RDI/business domains that are key elements in an integrated patient-based personalised medicine approach, such as new therapeutics, bioinformatics, medical device and telemedicine. Supporting this dynamic and steadily growing biocommunity is our main objective. Therefore, we provide our members with a portfolio of added-value activities and services to support them in their daily RDI and/or business challenges and to increase their national and international visibility.



Check out all open Calls for proposals on the Luxembourg Portal for Innovation and Research


  • 04-02-2016 Fast Track Diagnostics Wins 2015 Export Award Luxembourg

    On Wednesday, three organisations were awarded with the Export Award 2015 at a ceremony organised by the Office du Ducroire at the Chambre de Commerce in Luxembourg-Kirchberg. The ceremony was attended by circa 200 participants including HRH the Hereditary Grand Duke Guillaume. Robert Dennewald, Vice-President of the Chamber of Commerce, Pierre Gramegna, Minister of Finance, and Mrs. Ana BOATA, Economist Europe, Euler Hermes, spoke at the event.

  • 02-02-2016 Mitotech S.A. to initiate its first clinical study of a systemic formulation of SkQ1

    Mitotech S.A., a biotechnology company specializing in treatment of age-related disorders, announced a successful completion of its pre-clinical program and a start of clinical development for its systemic drug PlastomitinTM based on Mitotech’s lead compound SkQ1.

  • 28-01-2016 LIH launches new research unit in Health Economics and Evidence Synthesis

    Since July 2015, Prof Ngianga-Bakwin Kandala has been head of the newly created Health Economics and Evidence Synthesis Research Unit (HEESRU) at the Department of Population Health of the Luxembourg Institute of Health (LIH). HEESRU aims at developing and promoting the application of state-of-the-art economic methods to improve health and healthcare in Luxembourg.